Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II Trial to Evaluate the Early Bactericidal Activity, Safety and Tolerability of the Following: TMC207 Alone, TMC207 Plus Pyrazinamide,TMC207 Plus PA-824,PA-824 Plus Pyrazinamide and PA-824 Plus Pyrazinamide and Moxifloxacin, in Adult Patients With Newly Diagnosed, Smear-Positive Pulmonary Tuberculosis.
Brief Summary: The trial will evaluate the extended bactericidal activity of 14 consecutive days of oral administration of TMC207 alone, TMC207 with pyrazinamide, TMC207 with PA-824, PA-824 with pyrazinamide and PA-824 with moxifloxacin and pyrazinamide, as determined by the rate of change of log CFU in sputum over the time period Day 0-14 in participants with smear positive pulmonary tuberculosis (TB). A control group will receive standard treatment.


Options:
A: Arm Label: Standard dose rifampisin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Moxifloxacin | Arm Label: High dose rifampisin; Type: EXPERIMENTAL; Interventions: Drug: Moxifloxacin | Intervention Type: DRUG; Name: Moxifloxacin; Assigned to Arm(s): High dose rifampisin, Standard dose rifampisin
B: Arm Label: TMC207 Stage 1; Type: EXPERIMENTAL; Interventions: Drug: TMC207, Drug: Background regimen (BR) for MDR-TB (multi-drug resistant tuberculosis) | Arm Label: Placebo Stage 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Background regimen (BR) for MDR-TB (multi-drug resistant tuberculosis) | Arm Label: TMC207 Stage 2; Type: EXPERIMENTAL; Interventions: Drug: TMC207, Drug: Background regimen (BR) for MDR-TB (multi-drug resistant tuberculosis) | Arm Label: Placebo Stage 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Background regimen (BR) for MDR-TB (multi-drug resistant tuberculosis) | Intervention Type: DRUG; Name: TMC207; Assigned to Arm(s): TMC207 Stage 1, TMC207 Stage 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Stage 1, Placebo Stage 2 | Intervention Type: DRUG; Name: Background regimen (BR) for MDR-TB (multi-drug resistant tuberculosis); Assigned to Arm(s): Placebo Stage 1, Placebo Stage 2, TMC207 Stage 1, TMC207 Stage 2
C: Arm Label: TMC207; Type: EXPERIMENTAL; Interventions: Drug: TMC207 | Arm Label: TMC207 and pyrazinamide; Type: EXPERIMENTAL; Interventions: Drug: Pyrazinamide, Drug: TMC207 | Arm Label: PA-824 and pyrazinamide; Type: EXPERIMENTAL; Interventions: Drug: PA-824, Drug: Pyrazinamide | Arm Label: PA-824 and moxifloxacin and pyrazinamide; Type: EXPERIMENTAL; Interventions: Drug: PA-824, Drug: Moxifloxacin | Arm Label: Rifafour e-275 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rifafour | Arm Label: TMC207 and PA-824; Type: EXPERIMENTAL; Interventions: Drug: PA-824, Drug: TMC207 | Intervention Type: DRUG; Name: PA-824; Assigned to Arm(s): PA-824 and moxifloxacin and pyrazinamide, PA-824 and pyrazinamide, TMC207 and PA-824 | Intervention Type: DRUG; Name: Pyrazinamide; Assigned to Arm(s): PA-824 and pyrazinamide, TMC207 and pyrazinamide | Intervention Type: DRUG; Name: TMC207; Assigned to Arm(s): TMC207, TMC207 and PA-824, TMC207 and pyrazinamide | Intervention Type: DRUG; Name: Rifafour; Assigned to Arm(s): Rifafour e-275 mg | Intervention Type: DRUG; Name: Moxifloxacin; Assigned to Arm(s): PA-824 and moxifloxacin and pyrazinamide
D: Intervention Type: DRUG; Name: Gatifloxacin combined regimen; Assigned to Arm(s): N/A

Answer: C